Mosaic Family Wealth Partners LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,694 shares of the medical technology company's stock, valued at approximately $1,478,000.
Several other institutional investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the fourth quarter worth about $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker during the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 77.09% of the company's stock.
Stryker Price Performance
Shares of SYK stock opened at $338.80 on Monday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The stock's 50-day simple moving average is $324.61 and its 200-day simple moving average is $333.40.
Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker's dividend payout ratio (DPR) is currently 36.48%.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on SYK. Wolfe Research cut shares of Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research note on Friday, July 31st. Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. Piper Sandler dropped their target price on Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and an average price target of $386.28.
View Our Latest Analysis on SYK
Insiders Place Their Bets
In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company's stock.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.